repligen - RGEN
RGEN
Close Chg Chg %
118.32 -0.54 -0.46%
Closed Market
117.78
-0.54 (0.46%)
Volume: 797.31K
Last Updated:
Apr 2, 2026, 4:00 PM EDT
Company Overview: repligen - RGEN
RGEN Key Data
| Open $114.20 | Day Range 114.20 - 121.72 |
| 52 Week Range 102.97 - 175.57 | Market Cap $6.67B |
| Shares Outstanding 56.33M | Public Float 53.26M |
| Beta 1.19 | Rev. Per Employee N/A |
| P/E Ratio 136.88 | EPS $0.87 |
| Yield 0.00% | Dividend N/A |
| EX-DIVIDEND DATE | SHORT INTEREST N/A |
| AVERAGE VOLUME 930.83K |
RGEN Performance
| 1 Week | 6.96% | ||
| 1 Month | -1.84% | ||
| 3 Months | -28.34% | ||
| 1 Year | 5.22% | ||
| 5 Years | -39.74% |
RGEN Analyst Ratings
- Sell
- Under
- Hold
- Over
- Buy
Number of Ratings
22
Full Ratings ➔
About repligen - RGEN
Repligen Corp. is a global life sciences company, which engages in providing bioprocessing technologies and solutions used in the process of manufacturing biological drugs. It operates through the North America. Europe, and Asia Pacific Region or Other geographical segments. The company was founded by Alexander G. Rich and Paul R. Schimmel in May 1981 and is headquartered in Waltham, MA.
RGEN At a Glance
Repligen Corp.
41 Seyon Street
Waltham, Massachusetts 02453
| Phone | 1-781-250-0111 | Revenue | 738.26M | |
| Industry | Pharmaceuticals: Major | Net Income | 48.89M | |
| Sector | Health Technology | 2025 Sales Growth | 16.364% | |
| Fiscal Year-end | 12 / 2026 | Employees | 2,000 | |
| View SEC Filings |
RGEN Valuation
| P/E Current | 136.881 |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | 189.565 |
| Price to Sales Ratio | 12.554 |
| Price to Book Ratio | 4.382 |
| Price to Cash Flow Ratio | 78.93 |
| Enterprise Value to EBITDA | 58.075 |
| Enterprise Value to Sales | 12.449 |
| Total Debt to Enterprise Value | 0.075 |
RGEN Efficiency
| Revenue/Employee | 369,128.00 |
| Income Per Employee | 24,447.00 |
| Receivables Turnover | 4.655 |
| Total Asset Turnover | 0.255 |
RGEN Liquidity
| Current Ratio | 8.374 |
| Quick Ratio | 7.119 |
| Cash Ratio | 5.652 |
RGEN Profitability
| Gross Margin | 47.495 |
| Operating Margin | 8.303 |
| Pretax Margin | 8.45 |
| Net Margin | 6.623 |
| Return on Assets | 1.692 |
| Return on Equity | 2.397 |
| Return on Total Capital | 1.749 |
| Return on Invested Capital | 1.805 |
RGEN Capital Structure
| Total Debt to Total Equity | 32.759 |
| Total Debt to Total Capital | 24.676 |
| Total Debt to Total Assets | 23.39 |
| Long-Term Debt to Equity | 31.735 |
| Long-Term Debt to Total Capital | 23.905 |
- Income Statement
- Balance Sheet
- Cash Flow Statement
Annual Financials for Repligen - RGEN
Collapse All in section
| All values USD millions. | 2022 | 2023 | 2024 | 2025 | 5-year trend |
|---|---|---|---|---|---|
Sales/Revenue
| 801.54M | 632.36M | 634.44M | 738.26M | |
Sales Growth
| +19.54% | -21.11% | +0.33% | +16.36% | |
Cost of Goods Sold (COGS) incl D&A
| 371.61M | 355.09M | 350.44M | 387.62M | |
COGS excluding D&A
| - | - | - | - | - |
Depreciation & Amortization Expense
| 50.98M | 86.11M | 86.56M | 96.96M | |
Depreciation
| 23.90M | 54.56M | 51.89M | 57.86M | |
Amortization of Intangibles
| 27.09M | 31.56M | 34.67M | 39.10M | |
COGS Growth
| +24.87% | -4.45% | -1.31% | +10.61% | |
Gross Income
| 429.92M | 277.27M | 284.00M | 350.63M | |
Gross Income Growth
| +15.28% | -35.51% | +2.43% | +23.46% | |
Gross Profit Margin
| +53.64% | +43.85% | +44.76% | +47.50% |
| 2022 | 2023 | 2024 | 2025 | 5-year trend | |
|---|---|---|---|---|---|
SG&A Expense
| 224.73M | 227.94M | 261.35M | 289.34M | |
Research & Development
| 43.28M | 42.61M | 42.75M | 51.31M | |
Other SG&A
| 181.45M | 185.33M | 218.60M | 238.03M | |
SGA Growth
| +25.06% | +1.43% | +14.66% | +10.71% | |
Other Operating Expense
| - | - | - | - | - |
Unusual Expense
| (19.48M) | 14.31M | 57.24M | 6.13M | |
EBIT after Unusual Expense
| 224.67M | 35.03M | (34.59M) | 55.17M | |
Non Operating Income/Expense
| (2.55M) | 32.26M | 30.13M | 30.39M | |
Non-Operating Interest Income
| 6.98M | 24.14M | 35.83M | 27.57M | |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Interest Expense
| 2.98M | 10.58M | 22.57M | 23.17M | |
Interest Expense Growth
| -76.58% | +255.32% | +113.41% | +2.65% | |
Gross Interest Expense
| 2.98M | 10.58M | 22.57M | 23.17M | |
Interest Capitalized
| - | - | - | - | - |
Pretax Income
| 219.14M | 56.71M | (27.04M) | 62.38M | |
Pretax Income Growth
| +42.72% | -74.12% | -147.67% | +330.75% | |
Pretax Margin
| +27.34% | +8.97% | -4.26% | +8.45% | |
Income Tax
| 33.18M | 21.11M | (1.52M) | 13.49M | |
Income Tax - Current - Domestic
| 34.80M | 19.94M | 15.04M | 16.86M | |
Income Tax - Current - Foreign
| - | - | - | - | - |
Income Tax - Deferred - Domestic
| (1.62M) | 1.17M | (16.56M) | (3.37M) | |
Income Tax - Deferred - Foreign
| - | - | - | - | - |
Income Tax Credits
| - | - | - | - | - |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Other After Tax Income (Expense)
| - | - | - | - | - |
Consolidated Net Income
| 185.96M | 35.60M | (25.51M) | 48.89M | |
Minority Interest Expense
| - | - | - | - | - |
Net Income
| 185.96M | 35.60M | (25.51M) | 48.89M | |
Net Income Growth
| +44.95% | -80.86% | -171.68% | +291.64% | |
Net Margin Growth
| +23.20% | +5.63% | -4.02% | +6.62% | |
Extraordinaries & Discontinued Operations
| - | - | - | - | - |
Discontinued Operations
| - | - | - | - | - |
Net Income After Extraordinaries
| 185.96M | 35.60M | (25.51M) | 48.89M | |
Preferred Dividends
| - | - | - | - | - |
Net Income Available to Common
| 185.96M | 35.60M | (25.51M) | 48.89M | |
EPS (Basic)
| 3.353 | 0.6388 | -0.4561 | 0.8695 | |
EPS (Basic) Growth
| +43.79% | -80.95% | -171.40% | +290.64% | |
Basic Shares Outstanding
| 55.46M | 55.72M | 55.94M | 56.23M | |
EPS (Diluted)
| 3.2366 | 0.6314 | -0.4561 | 0.8644 | |
EPS (Diluted) Growth
| +44.47% | -80.49% | -172.24% | +289.52% | |
Diluted Shares Outstanding
| 57.45M | 56.38M | 55.94M | 56.56M | |
EBITDA
| 256.18M | 135.45M | 109.21M | 158.25M | |
EBITDA Growth
| +10.57% | -47.13% | -19.37% | +44.91% | |
EBITDA Margin
| +31.96% | +21.42% | +17.21% | +21.44% |
Snapshot
| Average Recommendation | BUY | Average Target Price | 188.056 | |
| Number of Ratings | 22 | Current Quarters Estimate | 0.465 | |
| FY Report Date | 06 / 2026 | Current Year's Estimate | 1.989 | |
| Last Quarter’s Earnings | 0.38 | Median PE on CY Estimate | N/A | |
| Year Ago Earnings | 1.71 | Next Fiscal Year Estimate | 2.525 | |
| Median PE on Next FY Estimate | N/A |
Earnings Per Share
| This Quarter | Next Quarter | This Fiscal | Next Fiscal | |
|---|---|---|---|---|
| # of Estimates | 17 | 17 | 19 | 17 |
| Mean Estimate | 0.47 | 0.52 | 1.99 | 2.53 |
| High Estimates | 0.50 | 0.56 | 2.48 | 2.70 |
| Low Estimate | 0.45 | 0.48 | 1.93 | 2.29 |
| Coefficient of Variance | 3.56 | 3.64 | 6.02 | 5.25 |
Analysts Recommendations
| Current | 1 Month Ago | 3 Months Ago | |
|---|---|---|---|
| BUY | 16 | 16 | 16 |
| OVERWEIGHT | 2 | 2 | 1 |
| HOLD | 4 | 4 | 6 |
| UNDERWEIGHT | 0 | 0 | 0 |
| SELL | 0 | 0 | 0 |
| MEAN | Buy | Buy | Overweight |
SEC Filings for Repligen - RGEN
| Filing Date | Type | Category | Amended |
|---|---|---|---|
| No results | |||
Insider Actions for Repligen - RGEN
| Date | Name | Shares | Transaction | Value |
|---|---|---|---|---|
| Mar 24, 2026 | James R. Bylund Chief Operating Officer | 8,315 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 24, 2026 | Ralf Kuriyel Senior VP, R&D | 20,062 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 24, 2026 | Ralf Kuriyel Senior VP, R&D | 5,669 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 24, 2026 | Jason K. Garland CFO | 8,315 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 24, 2026 | Olivier Dominique Loeillot Chief Executive Officer | 58,078 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 24, 2026 | Olivier Dominique Loeillot Chief Executive Officer | 25,890 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 24, 2026 | James R. Bylund Chief Operating Officer | 25,423 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 24, 2026 | Jason K. Garland CFO | 20,092 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 4, 2026 | Brian Robb Douglass CHIEF PRODUCT OFFICER | 8,319 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $124.97 per share | 1,039,625.43 |
| Mar 4, 2026 | Tony J. Hunt Director | 89,062 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $124.97 per share | 11,130,078.14 |
| Sep 12, 2025 | Tony J. Hunt Director | 129,758 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $116.34 per share | 15,096,045.72 |
| Sep 12, 2025 | Tony J. Hunt Director | 128,650 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $118.32 per share | 15,221,868.00 |
| Sep 12, 2025 | Tony J. Hunt Director | 125,388 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $119.64 per share | 15,001,420.32 |
| Sep 12, 2025 | Tony J. Hunt Director | 110,506 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $120.19 per share | 13,281,716.14 |
| Sep 12, 2025 | Tony J. Hunt Director | 102,922 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $121.42 per share | 12,496,789.24 |
| Sep 12, 2025 | Tony J. Hunt Director | 100,743 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $122.23 per share | 12,313,816.89 |
| Sep 12, 2025 | Tony J. Hunt Director | 182,344 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Aug 13, 2025 | Martin D. Madaus Director | 1,800 | Open market or private purchase of non-derivative security Non-derivative transaction at $112.13 per share | 201,834.00 |
| May 22, 2025 | Nicolas M. Barthelemy Director | 1,800 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| May 22, 2025 | Nicolas M. Barthelemy Director | 4,441 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |